StockDrifts LogoStockDrifts

Prestige Biologics 334970

Company
프레스티지바이오로직스Prestige Biologics
Insiders
1
Buys
6
Total Value
₩7M ($5K)
Avg Return
+0.82%
Last Filing
2026-07-09

Prestige Biologics (334970) has 6 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩7M ($5K) in reported transaction value. The earliest filing StockDrifts holds for Prestige Biologics is dated 2024-03-29; the most recent is 2026-07-09. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +0.82%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-07-09BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO3.6K₩1,830+0.8%₩7M ($5K)
2026-06-30BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO8.0K---
2026-06-29BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO16.2K---
2026-06-26BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO28.8K---
2026-06-25BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO22.0K---
2026-06-24BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO25.0K---
2025-05-29BUY주식매수선택권
동현철
Dong Hyeon-cheol
Other non-executive directors35.0K₩3,910-27.6%₩137M ($95K)
2024-09-25BUY유상신주취득
프레스티지바이오파마
Prestige Biopharma
-15.9M₩5,950-52.4%₩94.7B ($65.8M)
2024-03-29BUY주식매수선택권
동현철
Dong Hyeon-cheol
Other non-executive directors80.0K₩4,635-38.9%₩371M ($258K)
2024-03-29BUY주식매수선택권
양재영
Jaeyoung Yang
Managing Director22.5K₩4,635-38.9%₩104M ($72K)

Frequently asked questions

Who has been buying Prestige Biologics stock?
1 distinct insiders have filed 6 disclosed insider purchases in Prestige Biologics (334970), most recently on 2026-07-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Prestige Biologics have?
Prestige Biologics has 6 buy-side and 0 sell-side disclosures on record, covering ₩7M ($5K) in total reported value, spanning 2024-03-29 to 2026-07-09.
Where does StockDrifts get Prestige Biologics insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Prestige Biologics. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.